---
title: "Contineum Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294410383.md"
datetime: "2026-07-30T20:19:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294410383.md)
  - [en](https://longbridge.com/en/news/294410383.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294410383.md)
generator: "portal-rs"
---

# Contineum Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.4.

EBIT: As of FY2026 Q2, the actual value is USD -17.5 M.

The provided reference, a Form 8-K filing by Contineum Therapeutics, Inc., announces the issuance of a press release regarding the company’s financial results for the second quarter ended June 30, 2026. However, the document explicitly states that actual financial results, operational metrics, cash flow details, or any forward-looking outlook/guidance are not contained within this Form 8-K document. Therefore, no specific financial or operational metrics can be extracted from the given text.

### Related Stocks

- [CTNM.US](https://longbridge.com/en/quote/CTNM.US.md)

## Related News & Research

- [Contineum Therapeutics to present at Morgan Stanley Global Healthcare Conference](https://longbridge.com/en/news/297017645.md)
- [Systemair corrects dividend record date to Aug. 31, 2026 from Sept. 31 error](https://longbridge.com/en/news/297344953.md)
- [AgroGalaxy delays 2025 results release to Nov. 30, 2026](https://longbridge.com/en/news/297440664.md)
- [Cemat publishes H1 2026 interim report](https://longbridge.com/en/news/297006906.md)
- [Cybeats updates financial calendar, schedules Q2 fiscal 2026 results webcast](https://longbridge.com/en/news/297086797.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**